Search the Newsreel

Beazer shareholder pressure pushed Dream Finders buyout

Beazer Homes USA Inc. agreed to a buyout by Dream Finders Homes Inc. for $33.50 a share, totaling $915 million, largely due to shareholder pressure for a near-term cash premium. The article also covers other Jacksonville-area companies' financial results, including Rayonier Advanced Materials, Fidelity …

Faze Three consolidated net profit jumps 110% in Q1FY26

Autonomous Net Interception & AI Combine for Counter-UAS

ParaZero Technologies and Axon Vision have partnered to create a new Counter-UAS system that integrates net-based physical interception with artificial intelligence threat analysis. This non-explosive drone defense architecture is designed for sensitive critical infrastructure facilities like airports and energy facilities. The system utilizes passive …

AstraZeneca Stock And 2 Cash Flow Picks Trading Below Fair Value

Braze, Inc. (BRZE) CBO Astha Malik sells 33,656 shares in 10b5-1 plan trade

Braze, Inc.'s Chief Business Officer, Astha Malik, sold 33,656 shares of Class A common stock on August 10, 2026, at a weighted average price of $27.65 per share. This transaction was executed under a Rule 10b5-1 trading plan adopted on April 15, 2026. After …

Azenta (AZTA) Is Up 11.5% After Returning To Profit And Raising Revenue Outlook - Has The Bull Case Changed?

Azenta (AZTA) recently reported a return to profitability in Q3 2026, with net income of US$2.46 million and revenue of US$161.18 million, alongside a US$50 million share repurchase. The company also raised its full-year revenue guidance to US$613-US$618 million, signaling increased confidence in its …

Is Beazer Homes USA (BZH) Stock Outpacing Its Construction Peers This Year?

Maze Therapeutics (NASDAQ:MAZE) Earns "Buy" Rating from BTIG Research

BTIG Research has reaffirmed its "Buy" rating for Maze Therapeutics (NASDAQ:MAZE), setting a $46 price target, indicating a potential 68.44% upside. The company has a consensus "Buy" rating from analysts with an average target price of $66, despite some insider selling totaling approximately $3.9 …

Braze CTO Jonathan Hyman sells $760k in company stock

Braze CTO Jonathan Hyman sold Class A common stock worth over $760,000 in early August through a pre-arranged trading plan. Despite the insider sales, Braze shares have shown significant recent gains, and analysts maintain a positive outlook, with several initiating or reiterating Buy ratings …

Faze Three Q1 Results: Board Approves Unaudited Standalone & Consolidated Financials

AstraZeneca slips Wednesday, underperforms market

AstraZeneca PLC (AZN) shares fell 1.20% to £117.02 on Wednesday, underperforming the broader market as the FTSE 100 Index (UKX) also dropped. The company's stock closed 25.62% below its 52-week high.

Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of "Buy" by Brokerages

Maze Therapeutics (NASDAQ:MAZE) has received an average "Buy" rating from eleven brokerages, with an average 12-month price target of $66.00, significantly higher than its current trading price of $27.31. The company recently reported quarterly earnings per share of -$0.76, meeting estimates, while analysts anticipate …

Kazera Global Targets 30,000 Tonnes Per Month of Heavy Mineral Sands Output at Walviskop

AstraZeneca Pharma India AGM voting results confirm all resolutions passed

Companies & Markets Analysis 12/08/2026: Hill & Smith, ECO Animal Health, Titon Holdings, CLS Holdings, Balfour Beatty, 80 Mile, Atalaya Mining Copper SA, Evoke, Seeing Machines, Kazera Global, Savannah Resources, Alternative Income REIT, Predator

REG - Kazera Global PLC - SAI Operational Planning Update

How AstraZeneca’s $400bn deal unravelled

One Broadway deal to start: Hollywood mogul Ari Emanuel has struck a roughly £4.5bn deal to buy the theatre group behind West End venues including the Lyceum and the Savoy in a major bet that strong demand for live events is here to stay. …

AstraZeneca PLC (AZN) News, Articles, Events & Latest Updates

This article provides a compilation of recent news and updates concerning AstraZeneca PLC (AZN). Key topics include options market movements, hedge fund bullishness, and reports of potential acquisition talks with Bristol Myers Squibb. It also covers related pharmaceutical news such as Merck's performance and …

Maze Therapeutics Q2 loss widens, but $150M raise extends cash runway to 2029

Maze Therapeutics Q2 Results: EPS misses estimates by 4.11%

Maze Therapeutics reported a Q2 net loss of $44.7 million, missing analyst EPS estimates, but significantly boosted its cash reserves to $494.9 million, extending its operational runway to 2029. The company saw increased R&D and G&A expenses while advancing its key programs, MZE829 and …

Beazer Homes USA Inc (NYSE: BZH) Share Price, BZH Stock News, BZH Share Price & Updates

Maze Therapeutics (NASDAQ:MAZE) Announces Earnings Results

Maze Therapeutics (MAZE) reports $68.9M loss but ends Q2 with $494.9M in cash

Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Maze Therapeutics reported its second-quarter 2026 financial results, highlighting ongoing clinical trials and a strong financial position. The company's Phase 2 HORIZON trial for MZE829 in AMKD is on track with updated data expected in late 2026 or early 2027, and the Phase 2 …

Baazeem Trading Company Reports Earnings Results for the Second Quarter Ended June 30, 2026

AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn’t Buy This Merger Talk

AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock's biggest one-day drop since 2020, after reports that it held merger talks with U.S. rival Bristol-Myers Squibb Company (NYSE:BMY). A combined company would be worth close to $400 billion, the …

Beazer Homes (BZH): Donald Smith & Co. reports 10.3% stake in common stock

Donald Smith & Co., Inc. has reported a 10.3% beneficial ownership stake in Beazer Homes USA Inc., amounting to 2,814,181 common shares. This filing, a Schedule 13G, indicates that Donald Smith & Co. acts as an investment adviser, exercising sole voting and dispositive power …

Faze Three reshapes board with new independent director as senior member completes tenure

Do Options Traders Know Something About AstraZeneca Stock We Don't?

Investors in AstraZeneca PLC AZN need to pay close attention to the stock based on moves in the options market lately. That is because the Jan. 15, 2027 $115.00 Call had some of the highest implied volatility of all equity options today. What is …

Hedge Funds are Bullish on AstraZeneca PLC (AZN)

AstraZeneca PLC (NYSE:AZN) topped second-quarter profit expectations, with core earnings per share of $2.63 versus the $2.48 analysts expected. The firm reiterated its target of $80 billion in annual revenue by 2030. However, the quarter also brought fresh pipeline trouble: its rare disease drug …

Beazer Homes USA, Inc. (NYSE:BZH) Receives Consensus Rating of "Reduce" from Analysts

Analysts have given Beazer Homes USA, Inc. (NYSE:BZH) a consensus "Reduce" rating, with one analyst recommending a sell and three suggesting a hold. Recent downgrades from Oppenheimer and Texas Capital contributed to this sentiment. Despite this, institutional investors hold 85.65% of the stock, and …

Seazen Group Posts Strong Leasing Income but Modest Contracted Sales in July 2026

AstraZeneca stock outlook: Seller pressure limits upside for AZN

ParaZero Net Pods Selected for Autonomous C-UAS & Physical Interception

ParaZero Technologies has secured an initial order for its DefendAir Net Pods from a Tier-1 European defense manufacturer. These Net Pods will integrate controlled, net-based physical interception into autonomous Counter-UAS platforms, providing a critical layer for neutralizing drone threats. The modular design allows for …

Baazeem Trading's H1 Attributable Net Profit, Revenue Rise

AstraZeneca Pharma Approves ₹36 Dividend; Shares Fall 0.78%